Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial

The emergence of artemisinin resistance has raised concerns that the most potent antimalarial drug may be under threat. The currently recommended daily dose of artesunate (AS) is 4 mg/kg, and is administered for 3 days together with a partner antimalarial drug. This study investigated the impact of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2011-05, Vol.6 (5), p.e19283
Hauptverfasser:	Bethell, Delia, Se, Youry, Lon, Chanthap, Tyner, Stuart, Saunders, David, Sriwichai, Sabaithip, Darapiseth, Sea, Teja-Isavadharm, Paktiya, Khemawoot, Phisit, Schaecher, Kurt, Ruttvisutinunt, Wiriya, Lin, Jessica, Kuntawungin, Worachet, Gosi, Panita, Timmermans, Ans, Smith, Bryan, Socheat, Duong, Fukuda, Mark M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Amebicides Antimalarials Armed forces Artemisinin Artemisinins - administration & dosage Artemisinins - adverse effects Artemisinins - pharmacokinetics Artemisinins - pharmacology Artesunate Cambodia Cancer therapies Clinical trials Dosage Dose-Response Relationship, Drug Drug dosages Drug Resistance Drug therapy Female Genotype & phenotype Humans Immunology Malaria Malaria - drug therapy Male Maximum Tolerated Dose Medical research Medicine Neutropenia Neutropenia - chemically induced Parasitemia Parasitemia - drug therapy Parasites Parasitology Patients Pharmacodynamics Pharmacology Plasmodium falciparum Randomization Substance abuse treatment Vector-borne diseases Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!